All In MedTech

Device Trial Radar · NCT06229743

Biolinq Safety and Effectiveness Trial

Safety and Effectiveness Study of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

247

Actual

Start

Feb 29, 2024

Primary completion

Jun 10, 2024

Study completion Jun 10, 2024

Sponsor

Lead sponsor
Biolinq Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 29, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and effectiveness of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System, which is intended to be worn for up to five (5) days (up to 120 hours) in adults with diabetes mellitus (DM). Data collected from this study is intended to be used to support commercial marketing application(s) for the intended commercial patient population of non-insulin-users. All participants will be asked to wear the Biolinq System and a commercial CGM comparator for five to seven days while taking fingersticks on a commercial Self-Monitoring Blood Glucose Meter. Throughout the sensor wear all participants will come back to the clinic twice for in-clinic days where venous blood draws and fingersticks will be used to compare glucose measurements to a Lab Analyzer (YSI). At the end of sensor wear subjects will return to the clinic to have the sensors removed and then exit the study.

Conditions

  • Diabetes
  • Diabetes Mellitus

Interventions

  • Biolinq SystemDevice

    Participants will wear at least one Biolinq Sensor. The estimated glucose value from the Biolinq Sensor will be compared to a YSI 2300 glucose value from venous blood within a 5 minute window (paired samples).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In Target Color Indicator - BlueTime frame: 5 days
  2. In Target Color Indicator - YellowTime frame: 5 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Metabolic Care + Research Institute

    Escondido, California

  • Diablo Clinical Research

    Walnut Creek, California

  • Atlanta Diabetes Associates

    Atlanta, Georgia

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.